Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology.
It is a $57.8B healthcare company. Revenue grew 37.8% over the last year, it currently loses money, and it holds more cash than debt.
- Website
- natera.com
- Location
- Austin, TX
- Employees
- 6 140
- Sector
- Healthcare
- Founded
- 2004
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Valuation, Growth, Profitability, Quality and Moat lag behind.
Valuation25
- P/E vs own historyn/a · 10/25
- FCF yield0.1% · 5/25
- P/S21.3x · 0/25
- EV/EBITDAn/a · 10/25
Growth25
- Revenue CAGR38.6% · 25/25
- Net income CAGRn/a · 0/25
- EPS CAGR ~5Yn/a · 0/25
- Fwd implied growthn/a · 0/25
Profitability0
- ROIC-29.6% · 0/25
- ROE-11.7% · 0/25
- Net margin-7.1% · 0/25
- Operating margin-10.7% · 0/25
Health50
- Altman Zn/a · 0/25
- Current ratio3.00 · 25/25
- Interest coverage-57.8x · 0/25
- Net cash / debtNet cash · 25/25
Quality33
- Piotroski F6/9 · 15/25
- Beneish M-2.02 · 12/25
- FCF conversionn/a · 0/25
- Margin stabilityσ 20.2% · 6/25
Moat20
- ROIC >12% years0/6 yrs · 0/25
- Median gross margin43.2% · 20/25
- FCF-positive years2/10 yrs · 0/25
- Worst-year net marginworst -75.4% · 0/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2023FinancialRevenue crossed $1B$1.08B for the year
- 2020ProductNatera launched Renasight, a test to determine if there is a genetic cause for an individual's kidney…
- FY2019FinancialBecame debt-freecash now exceeds total debt
- 2019ProductNatera launched the Prospera dd-cfDNA transplant assessment test in 2019
- 2017ProductThe shares trade on the Nasdaq Global Select Market under the symbol "NTRA." In 2017, Natera launched the Vistara…
- 2015IPONatera conducted an initial public offering of common stock at a price of $18.00 per share
- 2013ProductThe following year, 2013, Natera launched the Panorama non-invasive prenatal test (NIPT)
- 2012ProductNatera's advanced carrier screening test, Horizon, launched in 2012
- 2010ProductThe company introduced the Anora miscarriage (POC) test
- 2009ProductNatera launched its first product, the Spectrum preimplantation genetic test, in 2009
- 2004FoundedNatera (previously Gene Security Network) was founded by Matthew Rabinowitz and Jonathan Sheena in 2004
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (65.2%)
- Revenue growing 37.8% year over year
- Net cash position after subtracting debt from cash
Watch-outs
- Not profitable — 7.1% net margin
- Thin interest coverage (-57.8×)
- Loss-making in 10 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+37.8% YoY
- Profitable — makes more than it spends-$192M TTM
- Profit growing — earnings are higher than last year-9.3% YoY
- Generates cash — cash left after running and investing$84.2M TTM
- Debt under control — could handle its obligationsmore cash than debt
- Established company — not a micro-cap — lower blow-up risk$57.8B market cap
- Not printing shares — share count not ballooning — you keep your slice+96.6% shares over ~5y
- Proven track record — years of profitability behind it0/10 profitable years
- Financially stable — balance sheet not near distresshealth score 25/100
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsno data
Peer comparisonNatera, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| NTRA this company | $57.8B | — | +37.8% | -7.1% | Strained |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: NTRA vs LLY · NTRA vs JNJ · NTRA vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/NTRA
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of NTRA on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $400.71 · market cap $57.8B.